Marty Makary has stepped down as FDA commissioner following mounting pressure over his disagreement with the Trump administration's stance on flavored vaping products.
The departure marks an early exit for Makary, who was tapped to lead the agency but found himself at odds with White House priorities. Sources say the physician privately expressed opposition to an administration decision greenlighting flavored vapes, a position that created friction within the agency leadership.
The FDA's top food safety official will assume the commissioner role in Makary's wake. The transition brings to a close a brief tenure marked by internal conflict over regulatory direction and public health policy priorities.
Makary had been expected to reshape the FDA under Trump's broader deregulatory agenda, but the flavored vape disagreement highlighted deeper tensions about how aggressively the administration wanted to roll back restrictions on nicotine products. The move to greenlight such products clashed with Makary's stated concerns about youth access and health outcomes.
The shakeup underscores how quickly leadership disputes can upend agency operations when top officials diverge from White House expectations. Makary's exit leaves questions about who will ultimately chart the FDA's course on vaping regulation, drug approval timelines, and other contentious health policy matters heading into a second Trump term.
Author Sarah Mitchell: "When a commissioner can't stomach his own boss's call on flavored vapes, somebody has to walk, and apparently it was going to be Makary."
Comments